Population Calling LIVE online launch event

A 60-minute LIVE webinar

Date: October 8, 2015 at 11 AM EDT / 5 PM CET

Ultra-fast analysis of 800 samples from the Alzheimer Disease Neuroimaging Initiative (ADNI)

During this LIVE webinar we will showcase the new Population Calling analysis module, part of our GENALICE MAP NGS data analysis suite. Our breakthrough new analysis module is capable to perform population calling on 800 Alzheimer Disease samples from the GENALICE Aligned Reads (GAR) format into the new GENALICE Variant Map (GVM) format in only one hour.

No longer for the ‘Happy Few’

Current NGS high-throughput sequencing platforms can produce tens of thousands individual genomes per year, enabling large-scale population genetics. Detection of sequence variants is best performed in the context of an entire cohort. Existing tools are not designed for analysis at scale. GENALICE also brings innovation to this field and enables every scientist to perform large-scale cohort studies.

Attend this LIVE event and:

  • Learn more about the GENALICE MAP and the new Population Calling analysis module, which allows individual patient level calls to take advantage of the population context, resulting in more reliable variant detection for each patient
  • Gain insight into the methods behind this ultra-fast sample processing technology, which only takes about 6 minutes per sample to perform the analysis
  • Create an understanding of the composition and new opportunities offered by the GVM file format
  • Become aware of the advantages offered by the Population Calling module; for example cost-effectiveness, incremental cohort building opportunities and easiness to query.

LIVE at American Society of Human Genetics 2015 Annual Meeting

This online live event can also be viewed at the GENALICE booth (#2031) at the ASHG 2015 Annual Meeting. On October 8, 2015 at 11 AM EDT (5 PM CET), the GENALICE MAP Population Calling module will be launched. You can participate online via the webinar or together with the GENALICE representatives at the ASHG booth.

Alzheimer Disease Neuroimaging Initiative (ADNI)

ADNI is an ongoing, longitudinal, multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer’s disease (AD). The ADNI study began in 2004 and included 400 subjects diagnosed with mild cognitive impairment (MCI), 200 subjects with early AD and 200 elderly control subjects. Mount Sinai Hospital is one of the main study sites.

There are no products listed under this category.